Bristol Myers Squibb reports 56-week Camzyos data in paediatric obstructive HCM
What's the update? On 6 November 2026, Bristol Myers Squibb presented 56-week results from the Phase 3 SCOUT-HCM trial as a late-breaker at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions in Chicago. The trial studied Camzyos (mavacamten) in children and adolescents aged 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a heart condition in which the muscle thickens and blocks blood flow out of the heart.
The results: Of 44 randomised participants, 43 completed the initial 28-week placebo-controlled period and then all received Camzyos through week 56. In patients on Camzyos throughout, the pressure gradient across the blocked heart outflow fell by an average of 48.1 mmHg from baseline at 56 weeks. No patient had a left ventricular ejection fraction below 50% — a key measure of the heart's pumping function — and no new safety signals appeared. Treatment-related side effects were uncommon: five events (two serious) across 56 weeks in the Camzyos group. Results were consistent with the 28-week data reported earlier.
Why it matters: Camzyos is the first cardiac myosin inhibitor — a drug that relaxes the over-contracting heart muscle — approved for paediatric patients weighing 30 kg or more with symptomatic oHCM, after US FDA approval in September 2026 based on the 28-week results. These 56-week data are the longest double-blind evaluation of this drug class in adolescents and support the durability of the treatment. The company also presented four-year follow-up from the drug's safety monitoring programme and up to five years of cardiac imaging data in adults.
Read more: Bristol Myers Squibb, 06 November 2026